Nektar Therapeutics (NKTR) Non-Current Deffered Revenue (2016 - 2020)
Nektar Therapeutics has reported Non-Current Deffered Revenue over the past 11 years, most recently at $2.5 million for Q4 2020.
- Quarterly results put Non-Current Deffered Revenue at $2.5 million for Q4 2020, down 3.52% from a year ago — trailing twelve months through Dec 2020 was $2.5 million (down 3.52% YoY), and the annual figure for FY2020 was $2.5 million, down 3.52%.
- Non-Current Deffered Revenue for Q4 2020 was $2.5 million at Nektar Therapeutics, down from $2.5 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for NKTR hit a ceiling of $60.1 million in Q2 2016 and a floor of $2.5 million in Q4 2020.
- Median Non-Current Deffered Revenue over the past 5 years was $12.1 million (2018), compared with a mean of $24.5 million.
- Biggest five-year swings in Non-Current Deffered Revenue: dropped 1.51% in 2017 and later crashed 79.71% in 2018.
- Nektar Therapeutics' Non-Current Deffered Revenue stood at $51.9 million in 2016, then plummeted by 63.34% to $19.0 million in 2017, then tumbled by 43.52% to $10.7 million in 2018, then crashed by 76.23% to $2.6 million in 2019, then dropped by 3.52% to $2.5 million in 2020.
- The last three reported values for Non-Current Deffered Revenue were $2.5 million (Q4 2020), $2.5 million (Q3 2020), and $2.5 million (Q2 2020) per Business Quant data.